Company / Operating Cash Flow
Enliven Therapeutics, Inc. Operating Cash Flow History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$73.2M
FY2024
5-year range
-$73.2M / -$32.1M
FY2020-FY2024
Trend
-19.5%
vs FY2023
Sector context
#110 of 216
Health Care
What the data says
At -$73M, Enliven Therapeutics, Inc.'s operating cash flow ranks #110 of 216 in the Health Care sector. Declined from -$32M to -$73M over the past 2 years.
Based on SEC 10-K filings.
-$73M in FY2024.
Declined from -$32M to -$73M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#110 of 216 in Health CareTop 51% of 216This company -$73.2M Sector average $659.0M
▼
-111.1% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow decreased 19.5% year-over-year.
- Ranks #110 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$73.2M | -19.5% |
| FY2023 | -$61.3M | -91.0% |
| FY2022 | -$32.1M | +31.4% |
| FY2021 | -$46.8M | -25.1% |
| FY2020 | -$37.4M | -70.9% |
| FY2019 | -$21.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026